Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Liver Failure Acute Clear all
Active, not recruiting Phase 2 Interventional

TReatment for ImmUne Mediated PathopHysiology

NCT04862221
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Interventions
High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
1 Year to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 30, 2026, 10:24 AM EDT
Not listed Phase 2 Interventional

Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome

NCT05875948
View directory record Official record
Conditions
Hepatorenal Syndrome, Acute Kidney Injury
Interventions
R2R01, Terlipressin
Drug
Lead sponsor
River 2 Renal Corp.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 30, 2026, 10:24 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Continuous Renal Replacement Therapy in the Setting of Orthotopic Liver Transplant

NCT01619449
View directory record Official record
Conditions
Acute Kidney Injury, Liver Disease, Chronic Kidney Disease, End Stage Kidney Disease
Interventions
Renal replacement therapy
Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 3 Interventional Results available

N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure

NCT00248625
View directory record Official record
Conditions
Acute Liver Failure, Hepatic Encephalopathy
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
Up to 18 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Oct 30, 2026, 10:24 AM EDT
Not listed Phase 1 Interventional

Use of Direct Peritoneal Resuscitation in High-risk Liver Transplant Recipients

NCT05195125
View directory record Official record
Conditions
End Stage Liver DIsease, Obesity, Acute Kidney Injury
Interventions
Direct Peritoneal Resuscitation
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 30, 2026, 10:24 AM EDT
Completed No phase listed Observational

A Multi-Center Trial to Study Acute Liver Failure in Adults

NCT00518440
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure, Acute Liver Injury
Interventions
Not listed
Lead sponsor
William Lee
Other
Eligibility
18 Years and older
Enrollment
3,488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2019
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury

NCT01548690
View directory record Official record
Conditions
Acute Liver Failure, Acute Liver Injury
Interventions
Ornithine Phenylacetate
Drug
Lead sponsor
William Lee
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
11
States / cities
San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 30, 2026, 10:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prognostic Indicators as Provided by the EPIC ClearView

NCT01476995
View directory record Official record
Conditions
Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation, Hypertension, Pyelonephritis, Acute Renal Failure, Renal Failure, Viral Hepatitis, Alcoholic Hepatitis, Steatohepatitis, Cirrhosis, Asthma, COPD, Bronchitis, Emphysema, Pneumonia, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Diverticulitis, Peptic Ulcer Disease, Irritable Bowel Syndrome, Cholecystitis, Pancreatitis, Malabsorption Disorders, Celiac Sprue, Diabetes
Interventions
Not listed
Lead sponsor
Epic Research & Diagnostics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 3 Interventional

Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen

NCT00004467
View directory record Official record
Conditions
Acute Liver Failure
Interventions
N-acetylcysteine (NAC), Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 70 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
25
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 1 Interventional

miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial

NCT06285253
View directory record Official record
Conditions
Acute Liver Failure, Acute Liver Injury, Drug Induced, Acute on Chronic Liver Failure (ACLF), Acute Alcoholic Hepatitis
Interventions
miroliverELAP treatment
Combination Product
Lead sponsor
Miromatrix Medical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
8
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 30, 2026, 10:24 AM EDT
Suspended No phase listed Observational

Longitudinal Study of Mitochondrial Hepatopathies

NCT01148550
View directory record Official record
Conditions
Acute Liver Failure, Mitochondrial Diseases, End Stage Liver Disease, Respiratory Chain Deficiencies, Mitochondrial, Disorder of Fatty Acid Oxidation
Interventions
Not listed
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
Up to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2029
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 30, 2026, 10:24 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

NEPH-ROSIS (NEPHrology in CirRhOSIS) Pilot Trial: A Trial to Treat Acute Kidney Injury Among Hospitalized Cirrhosis Patients

NCT06000748
View directory record Official record
Conditions
Acute Kidney Injury, Cirrhosis, Portal Hypertension, Hepatorenal Syndrome, Acute Tubule Necrosis, Prerenal Failure
Interventions
MAP-Target Algorithm
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 30, 2026, 10:24 AM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF)

NCT00832728
View directory record Official record
Conditions
Fulminant Hepatic Failure
Interventions
Standard of Care, ELAD®
Other · Device
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
10 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Oct 30, 2026, 10:24 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF)

NCT01875874
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure, Primary Graft Non-Function, Surgically-Induced Liver Failure
Interventions
ELAD
Biological
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
18
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 30, 2026, 10:24 AM EDT
Terminated Phase 3 Interventional Results available

To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure

NCT01829347
View directory record Official record
Conditions
Severe Acute Alcoholic Hepatitis
Interventions
ELAD, Standard of Care treatment
Biological · Other
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
21
States / cities
Little Rock, Arkansas • San Diego, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 30, 2026, 10:24 AM EDT
Terminated Phase 3 Interventional Results available

Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function

NCT04258423
View directory record Official record
Conditions
Kidney Failure
Interventions
Tacrolimus, Everolimus
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 30, 2026, 10:24 AM EDT
Not listed Not applicable Interventional

Timing of Acute Palliative Care Consultation in Critically Ill Patients

NCT02858778
View directory record Official record
Conditions
Multiple Organ Failure, End Stage Cardiac Failure, End Stage Chronic Obstructive Airways Disease, Chronic Kidney Disease Stage 5, Hepatic Encephalopathy, Sepsis, Dementia, Multiple Sclerosis, Parkinson's Disease, In-Hospital Cardiac Arrest, Solid Organ Cancer
Interventions
Early order of palliative care consultation
Other
Lead sponsor
Wayne State University
Other
Eligibility
65 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
2
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 30, 2026, 10:24 AM EDT
Terminated Phase 2 Interventional

A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy

NCT06987968
View directory record Official record
Conditions
Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF), Decompensated Cirrhosis
Interventions
VS-01 on top of SOC (Active Treatment Group), SOC
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 79 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers

NCT07110441
View directory record Official record
Conditions
Acute-on-Chronic Liver Failure
Interventions
Single Dose G1090N, Multiple dosing of G1090N
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 2Phase 3 Interventional Results available

13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF

NCT02786836
View directory record Official record
Conditions
Acute Liver Failure
Interventions
13C-Methacetin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 30, 2026, 10:24 AM EDT
Terminated Phase 3 Interventional Results available

Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%

NCT03702920
View directory record Official record
Conditions
Acute-On-Chronic Liver Failure
Interventions
SMT + PE-A 5%, Standard Medical Treatment
Biological · Other
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
18 Years to 79 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Coronado, California • Los Angeles, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 30, 2026, 10:24 AM EDT
Completed Phase 3 Interventional Results available

Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure

NCT01471028
View directory record Official record
Conditions
Acute Alcoholic Hepatitis
Interventions
ELAD treatment, Standard of care (Control)
Biological · Other
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 30, 2026, 10:24 AM EDT
Withdrawn Phase 1 Interventional

Hepatocyte Transplantation for Acute Decompensated Liver Failure

NCT01345565
View directory record Official record
Conditions
Liver Failure Acute
Interventions
human hepatocytes
Drug
Lead sponsor
Ira Fox
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 30, 2026, 10:24 AM EDT
Terminated Phase 3 Interventional Results available

Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD

NCT02612428
View directory record Official record
Conditions
Acute Alcoholic Hepatitis
Interventions
ELAD System, Standard of Care (Control)
Biological · Other
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Little Rock, Arkansas • Coronado, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 30, 2026, 10:24 AM EDT